Urinary Metabolite Biomarkers for the Detection of Synthetic Cannabinoid ADB-BUTINACA Abuse
- PMID:34387654
- DOI: 10.1093/clinchem/hvab134
Urinary Metabolite Biomarkers for the Detection of Synthetic Cannabinoid ADB-BUTINACA Abuse
Abstract
Background: (S)-N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3carboxamide (ADB-BUTINACA) is an emerging synthetic cannabinoid that was first identified in Europe in 2019 and entered Singapore's drug scene in January 2020. Due to the unavailable toxicological and metabolic data, there is a need to establish urinary metabolite biomarkers for detection of ADB-BUTINACA consumption and elucidate its biotransformation pathways for rationalizing its toxicological implications.
Methods: We characterized the metabolites of ADB-BUTINACA in human liver microsomes using liquid chromatography Orbitrap mass spectrometry analysis. Enzyme-specific inhibitors and recombinant enzymes were adopted for the reaction phenotyping of ADB-BUTINACA. We further used recombinant enzymes to generate a pool of key metabolites in situ and determined their metabolic stability. By coupling in vitro metabolism and authentic urine analyses, a panel of urinary metabolite biomarkers of ADB-BUTINACA was curated.
Results: Fifteen metabolites of ADB-BUTINACA were identified with key biotransformations being hydroxylation, N-debutylation, dihydrodiol formation, and oxidative deamination. Reaction phenotyping established that ADB-BUTINACA was rapidly eliminated via CYP2C19-, CYP3A4-, and CYP3A5-mediated metabolism. Three major monohydroxylated metabolites (M6, M12, and M14) were generated in situ, which demonstrated greater metabolic stability compared to ADB-BUTINACA. Coupling metabolite profiling with urinary analysis, we identified four urinary biomarker metabolites of ADB-BUTINACA: 3 hydroxylated metabolites (M6, M11, and M14) and 1 oxidative deaminated metabolite (M15).
Conclusions: Our data support a panel of four urinary metabolite biomarkers for diagnosing the consumption of ADB-BUTINACA.
Keywords: ADB-BUTINACA; metabolic reaction phenotyping; metabolite profiling; synthetic cannabinoid; urinary biomarker.
© American Association for Clinical Chemistry 2021. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Similar articles
- The metabolism of the synthetic cannabinoids ADB-BUTINACA and ADB-4en-PINACA and their detection in forensic toxicology casework and infused papers seized in prisons.Kronstrand R, Norman C, Vikingsson S, Biemans A, Valencia Crespo B, Edwards D, Fletcher D, Gilbert N, Persson M, Reid R, Semenova O, Al Teneiji F, Wu X, Dahlén J, NicDaéid N, Tarbah F, Sutcliffe OB, McKenzie C, Gréen H.Kronstrand R, et al.Drug Test Anal. 2022 Apr;14(4):634-652. doi: 10.1002/dta.3203. Epub 2021 Dec 10.Drug Test Anal. 2022.PMID:34811926
- Detection of ADB-BUTINACA Metabolites in Human Urine, Blood, Kidney and Liver.Kavanagh P, Pechnikov A, Nikolaev I, Dowling G, Kolosova M, Grigoryev A.Kavanagh P, et al.J Anal Toxicol. 2022 Jul 14;46(6):641-650. doi: 10.1093/jat/bkab088.J Anal Toxicol. 2022.PMID:34341821
- New Synthetic Cannabinoid ADB-BUTINACA-Related Death of a Police Dog.Tokarczyk B, Suchan M, Adamowicz P.Tokarczyk B, et al.J Anal Toxicol. 2023 Mar 21;47(2):e23-e28. doi: 10.1093/jat/bkac097.J Anal Toxicol. 2023.PMID:36472351
- [Research Progress on Metabolite Identification of Synthetic Cannabinoid New Psychoactive Substances].Li L, Zhao JB, Yan H, Liu WH, Xiang P, Wu HJ.Li L, et al.Fa Yi Xue Za Zhi. 2021 Aug;37(4):459. doi: 10.12116/j.issn.1004-5619.2021.310602.Fa Yi Xue Za Zhi. 2021.PMID:34725997Review.Chinese.
- Involuntary 5F-ADB-related intoxication following e-cigarette use.Salle S, Sevestre C, Richeval C, Hakim F, Allorge D, Gaulier JM.Salle S, et al.Int J Legal Med. 2021 Jul;135(4):1467-1470. doi: 10.1007/s00414-021-02561-8. Epub 2021 Mar 25.Int J Legal Med. 2021.PMID:33765158Review.
Cited by
- Adulteration of low-delta-9-tetrahydrocannabinol products with synthetic cannabinoids: Results from drug checking services.Monti MC, Zeugin J, Koch K, Milenkovic N, Scheurer E, Mercer-Chalmers-Bender K.Monti MC, et al.Drug Test Anal. 2022 Jun;14(6):1026-1039. doi: 10.1002/dta.3220. Epub 2022 Feb 2.Drug Test Anal. 2022.PMID:34997693Free PMC article.
- Quantification of MDMB-4en-PINACA and ADB-BUTINACA in human hair by gas chromatography-tandem mass spectrometry.Wang Y, Pan Y, Yang H, Liu J, Wurita A, Hasegawa K.Wang Y, et al.Forensic Toxicol. 2022 Jul;40(2):340-348. doi: 10.1007/s11419-022-00615-z. Epub 2022 Mar 17.Forensic Toxicol. 2022.PMID:36454410
- Study of the Metabolic Profiles of "Indazole-3-Carboxamide" and "Isatin Acyl Hydrazone" (OXIZID) Synthetic Cannabinoids in a Human Liver Microsome Model Using UHPLC-QE Orbitrap MS.Xiang J, Wen D, Zhao J, Xiang P, Shi Y, Ma C.Xiang J, et al.Metabolites. 2023 Apr 18;13(4):576. doi: 10.3390/metabo13040576.Metabolites. 2023.PMID:37110234Free PMC article.
- Portable Digital Linear Ion Trap Mass Spectrometer Based on Separate-Region Corona Discharge Ionization Source for On-Site Rapid Detection of Illegal Drugs.Li L, Zhang T, Wang D, Zhang Y, He X, Wang X, Li P.Li L, et al.Molecules. 2022 May 30;27(11):3506. doi: 10.3390/molecules27113506.Molecules. 2022.PMID:35684444Free PMC article.
- The metabolic profile of the synthetic cannabinoid receptor agonist ADB-HEXINACA using human hepatocytes, LC-QTOF-MS and synthesized reference standards.Baginski SR, Rautio T, Nisbet LA, Lindbom K, Wu X, Dahlén J, McKenzie C, Gréen H.Baginski SR, et al.J Anal Toxicol. 2023 Dec 12;47(9):826-834. doi: 10.1093/jat/bkad065.J Anal Toxicol. 2023.PMID:37747838Free PMC article.